AstraZeneca and Daiichi Sankyo Report Updated DESTINY-Breast06 Data for Enhertu in HER2-Low Breast Cancer
Biotechnology Media Insights
Editorial Team · July 22, 2025
AstraZeneca and Daiichi Sankyo present updated Phase 3 DESTINY-Breast06 data showing Enhertu significantly improves outcomes in HER2-low and HER2-ultralow breast cancer.
AstraZeneca and Daiichi Sankyo today presented updated data from the Phase 3 DESTINY-Breast06 trial evaluating Enhertu (trastuzumab deruxtecan) in patients with HER2-low and HER2-ultralow hormone receptor-positive, HER2-negative metastatic breast cancer. The updated data showed a median progression-free survival of 13.2 months with Enhertu compared to 8.1 months with chemotherapy.
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.